AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06135298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CERAMENT BONE VOID FILLER (BVF)
Description: In addition to the standard surgical procedure, in the study group, after creating the canal with 10 mm drill bit and partly insertion of the helical blade, the synthetic bone void filler CaS/HA will be injected. The helical blade will be inserted partially with gentle blows with a hammer, 2.5 cm from its final intended position. The injectable CaS/HA biomaterial will be mixed as per the manufacturer guidelines and the paste will be transferred into an injection syringe. At t = 2.5 min from the start of mixing, 2-3 mL of BVF paste will be injected by a CE marked Introducer Needle connected to the injection syringe, through the hollow helical blade. Finally, the helical blade will be inserted to its end position with gentle blows with a hammer. Remaining material approximately 2 mL still being moldable will be manually deposited in the trochanteric fracture void.
Study NCT05339412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life
Description: The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
Study NCT06268041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Aerobic Training
Description: Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
Study NCT06268041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
Study NCT04999202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2416964
Description: Oral, twice or three times daily
Study NCT05230368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 1
Description: Decitabine administration (5mg/m²) at days 1, 2, 3
Study NCT05230368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 1
Description: Romidepsin administration (5mg/m²) at days 4, 11, 18
Study NCT05230368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 2
Description: Decitabine administration (5mg/m²) at days 35, 36, 37
Study NCT05230368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 2
Description: Romidepsin administration (5mg/m²) at days 38, 45, 52
Study NCT05230368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 3
Description: Decitabine administration (5mg/m²) at days 70, 71, 72
Study NCT05230368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 3
Description: Romidepsin administration (5mg/m²) at days 73, 80, 87
Study NCT05230368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine cycle 4
Description: Decitabine administration (5mg/m²) at days 105, 106, 107
Study NCT05230368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin cycle 4
Description: Romidepsin administration (5mg/m²) at days 108, 115, 122
Study NCT05837845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
Study NCT05837845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Participants will receive 12-16 sessions of Cognitive Processing Therapy
Study NCT05837845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MDMA-assisted Therapy
Description: Participants assigned to MDMA and d-amphetamine will undergo a therapeutic approach, which is detailed in the MDMA-Assisted Therapy Treatment Manual and administered by MAPS-trained therapists. In brief, this therapy is guided by the subject's own recollections of traumatic events. The subject and two therapists provide a comfortable and supportive environment and allow the subject to guide the discussion. Subjects are encouraged to experience and express fear, anger, and grief with less likelihood of feeling overwhelmed by these emotions. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. In addition, feelings of empathy, love, and deep appreciation often emerge, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present.
Study NCT04999202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2416964
Description: The highest dose determined safe in combination with pembrolizumab in the dose escalation part or a lower dose. More than one dose may be explored in the dose expansion.
Study NCT04999202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as a dose of 200 mg using a 30-minute IV infusion every 3 weeks
Study NCT06633965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIDANET
Description: AIDANET is a fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions.
Study NCT05408611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
Study NCT05408611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupressure
Description: Placebo acupressure is manual pressure applied to unreal acupressure points.
Study NCT04950309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQUID MEG
Description: MEG recordings acquired on a standard whole brain SQUID MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
Study NCT04950309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPM MEG
Description: MEG recordings acquired on an investigational OPM MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
Study NCT06340347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: a single dose of osivelotor administered by mouth under fasted conditions~Other Names:~PF-07940367
Study NCT06386003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.
Study NCT05482789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 10 microgram injected sub-cutaneously once
Study NCT05377021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle change
Description: In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention.
Study NCT05377021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle change
Description: In the project, 33 women in the first group will receive diet intervention for 12 weeks, and 33 women in the second group will receive diet and exercise combination intervention.
Study NCT05759338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revian Red All LED cap
Description: The cap is a dual-band LED light therapy wireless smart cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women.
Study NCT06307626 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe
Study NCT06307626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: Subcutaneous placebo given by prefilled syringe
Study NCT05327946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 770371
Description: BI 770371
Study NCT05327946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezabenlimab
Description: ezabenlimab
Study NCT06059144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous norepinephrine
Description: Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.
Study NCT05002205 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be followed up by means of online surveys and 2 study visits.
Study NCT05002205 — intervention group
Intervention type: OTHER
Intervention: spirometry
Description: During two study visits, the lung function will be measured (FVC, FEV1)
Study NCT05002205 — intervention group
Intervention type: OTHER
Intervention: ECG
Description: During two study visits, the presence of arrhythmia will be explored.
Study NCT05311839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching
Study NCT05002205 — intervention group
Intervention type: OTHER
Intervention: 1 minute sit to stand test
Description: Physical endurance is tested during 2 study visits.
Study NCT05002205 — intervention group
Intervention type: OTHER
Intervention: Vital parameters
Description: blood pressure, pulse, weight
Study NCT05311839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thera band
Description: graded Thera band exercises for shoulder flexion, abduction, internal, and external rotation
Study NCT04744116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellular Therapy
Description: Given ds-MSCs IV
Study NCT04744116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Given PO
Study NCT04744116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT04775238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver nanoparticles
Description: AgNPs (19±5 nm)
Study NCT04775238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Copper nanoparticles
Description: CuNPs (150-350 nm)
Study NCT06452654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty Injectable Product
Description: Vaccination
Study NCT06452654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Vaccination
Study NCT06203184 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: video based exercises
Description: Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
Study NCT06203184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video based exercises
Description: Respiratory muscle training and other factors will be examined through 12 weeks of video-based game exercises.
Study NCT05498285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPSCALER app
Description: Usage of mobile app to guide rehabilitation after surgery
Study NCT04850404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal nerve block
Description: All Patients of group A-M will be administered with rectus abdominis block combined with TAPB after anesthesia. Rocuronium was infused continuously (concentration: 1 mg/ml) when TOF recovered to 1. The starting rate was 0.3mg/kg/h, and the TOF count was maintained between 1\~3 (moderate NMB) and recorded during the operation. Whether and how to add rocuronium was based on TOF count and request of surgeons. When TOF Watch- SX showed 4 or ratio, the investigators increased the speed of rocuronium pump infusion and record the score at the time of shallow NMB. When the chief surgeon thought the vision could not satisfy the needs of the operation, rocuronium 0.1mg/kg in bolus was added as a rescue. Then, the pump speed was lowered or even decreased to 0 to make the TOF count recover to 1\~3 as soon as possible.
Study NCT05925634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RPE (usual care)
Description: Patients in the active comparator group will follow standard exercise prescription protocols in cardiac rehabilitation.
Study NCT05925634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GXT+THHR (intervention)
Description: Patients in the personalized care group will perform a graded exercise test and the peak heart rate from the test will allow the researcher to calculate a target heart rate range (THRR). Then, the patients will receive psychoeducational feedback (PF) about their test results and exercise performance. After PF, their THRR will be reviewed and how it will be used to guide exercise intensity in CR will be discussed.
Study NCT04704154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, (Stivarga, BAY73-4506)
Description: Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets).
Study NCT04704154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (Opdivo)
Description: 480 mg administered on Day 1 of each treatment cycle.
Study NCT05999786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: early rehabiliation swallowing program
Description: not receiving early rehabilitation swallowing program from before and after surgery
Study NCT05999786 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: not receiving early rehabilitation swallowing program
Description: the Taiwan Dysphagia Society's publicly shared swallowing exercises for dysphagia, which is from before and after surgery
Study NCT05322070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide Intravitreal Implant 0.18 mg
Description: YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
Study NCT05616507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fucoidan
Description: It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
Study NCT05936528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effect
Study NCT06331403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Group Intervention
Description: Weekly virtual group meetings with the study interventionist(s) and up to 9 other female cancer survivors over an approximately 6 week period. The group program includes topics related to coping with physical health changes, managing social factors relevant to sexual well-being, and managing thoughts and feelings related to sexual well-being changes.
Study NCT04863989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tube thoracostomy
Description: insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
Study NCT04863989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tube thoracostomy
Description: insertion of intercostal tube for drainage of traumatic hemothorax or pneumothorax
Study NCT05061537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07263689
Description: Genetically engineered oncolytic vaccinia virus
Study NCT05061537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2
Study NCT06056921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 targeted CAR-T cells
Description: A single infusion of CD19 CAR-T cells will be administered intravenously
Study NCT05736965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor 60mg, PO d3,10,17
Study NCT05736965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75mg/m2, IV d1-3, 8-9, 15-16
Study NCT05736965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 100mg PO on day 1 and 200mg on day 2, 400mg on day 3-14
Study NCT06422403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Dosing Interval - A
Description: Nivolumab 360mg 6 weekly (up to 2 years) + XELOX Nivolumab 240mg 4 weekly (up to 2 years) + FOLFOX
Study NCT06422403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Dosing Interval - B
Description: Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)
Study NCT06422403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Dosing Interval - C
Description: Pembrolizumab 200mg 6 weekly (up to 2 years)
Study NCT06422403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - A
Description: Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX
Study NCT06422403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - B
Description: Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)
Study NCT06422403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - C
Description: Pembrolizumab 200mg 3 weekly (up to 2 years)
Study NCT05554159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Fitbit Program
Description: Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
Study NCT05554159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Exercise Program
Description: Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
Study NCT05266963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CREON
Description: The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
Study NCT05266963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05379634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered intravenously in double-blind period and LTE period.
Study NCT05379634 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nipocalimab matching placebo will be administered intravenously in double-blind period.
Study NCT05379634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Prednisone or equivalent will be administered orally as Glucocorticoid.
Study NCT05379634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisone or equivalent will be administered orally as Glucocorticoid.
Study NCT06107764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittant theta burst stimulation (iTBS)
Description: iTBS consists of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.
Study NCT06107764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous theta burst stimulation (cTBS)
Description: cTBS consists of 3 pulses at 50 Hz repeated at 5 Hz (every 200ms) continuously for a total of 600 pulses
Study NCT06107764 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: sham rTMS does not deliver a significant change in magnetic field strength